In fact, multiple agents and chemotherapeutic drugs that have been granted for marketing or in clinical trials have been recognized as selective necroptosis inducer in cancer cells in specific cancer types, including shikonin and its analogs [41, 157], TRAIL [16], obatoclax [158], metal nanoparticles [148] et cetera. The gene discussed is TNFSF10; the disease is cancer.